CNBX Pharmaceuticals Inc.

0.0003

+0.000020.19%

Volume:7.34M

Turnover:1.49K

Market Cap:306.44K

PE:-0.33

High:0.0003

Open:0.0002

Low:0.0002

Close:0.0002

52wk High:0.0063

52wk Low:0.0001

Shares:1.23B

Float Shares:1.23B

Volume Ratio:1.59

T/O Rate:0.60%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0007

EPS(LYR):-0.0035

ROE:-4289.36%

ROA:-585.51%

PB:-0.12

PE(LYR):-0.07

Loading ...

Overview Company News Filings

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CNBX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CNBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNBX\",,,,,undefined,":{"symbol":"CNBX","market":"US","secType":"STK","nameCN":"CNBX Pharmaceuticals Inc.","latestPrice":0.00025,"timestamp":1778684520000,"preClose":0.000208,"halted":0,"volume":7340010,"delay":15,"changeRate":0.201923076923077,"floatShares":1225042440,"shares":1225768095,"eps":-0.000749,"marketStatus":"Trading","change":0.000042,"latestTime":"05-13 11:02:00 EDT Delay","open":0.0002,"high":0.00025,"low":0.0002,"amount":1485.002197161,"amplitude":0.240385,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.000749,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778702400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"PINK","adjPreClose":0.000208,"volumeRatio":1.591489},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNBX\",,,,,undefined,":{"symbol":"CNBX","floatShares":1225042440,"roa":"-585.51%","roe":"-4289.36%","lyrEps":-0.003463,"volumeRatio":1.591489,"shares":1225768095,"dividePrice":0,"high":0.00025,"amplitude":0.240385,"preClose":0.000208,"low":0.0002,"week52Low":0.0001,"pbRate":"-0.12","week52High":0.0063,"institutionHeld":0,"latestPrice":0.00025,"eps":-0.000749,"divideRate":0,"volume":7340010,"delay":15,"ttmEps":-0.000749,"open":0.0002,"prevYearClose":0.0004,"prevWeekClose":0.0003,"prevMonthClose":0.0002,"prevQuarterClose":0.0001,"fiveDayClose":0.0003,"twentyDayClose":0.0001,"sixtyDayClose":0.0001},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-07-15","symbol":"CNBX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1721016000000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-01-12","symbol":"CNBX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1705035600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-11-29","symbol":"CNBX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1701234000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2022-05-12","symbol":"CNBX","defaultRemindTime":1652362200000,"type":"split","dateTimestamp":1652328000000,"forFactor":1000000,"toFactor":8333,"ratio":120.00480019200768}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNBX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNBX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627404234","title":"CNBX Pharma Q2 FY26 net loss narrows 36.8% to $44,098","url":"https://stock-news.laohu8.com/highlight/detail?id=2627404234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627404234?lang=en_us&edition=fundamental","pubTime":"2026-04-14 23:36","pubTimestamp":1776181015,"startTime":"0","endTime":"0","summary":"CNBX Pharmaceuticals posted a net loss of $44,098 for the three months ended Feb. 28, 2026, narrowing from $69,788 a year earlier.Total operating expenses rose 12.7% to $72,963, driven by higher general and administrative costs tied mainly to salary expense of $55,519.Financial income was $28,865 versus a financial loss of $5,045 a year earlier, reflecting income tied to realization of convertible loans.For the six months ended Feb. 28, 2026, net loss widened to $157,817 from $104,140.Cash totaled $12,154 at Feb. 28, 2026, while management expects at least $1,000,000 in expenses over the next 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNBX Pharmaceuticals Inc. published the original content used to generate this news bri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL6BlNTW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620422847","title":"CNBX Pharmaceuticals Signs USD 45,000 Promissory Note With 3i L.P","url":"https://stock-news.laohu8.com/highlight/detail?id=2620422847","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620422847?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:31","pubTimestamp":1773750719,"startTime":"0","endTime":"0","summary":"CNBX Pharmaceuticals entered into a non-convertible promissory note with 3i for USD 45,000. The note is due July 1, 2026, and carries 5% simple annual interest. CNBX said it plans to use the proceeds for working capital and expenditures.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNBX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLbLZxkp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603661157","title":"CNBX Pharmaceuticals Inc. posts Q1 net loss of USD 113.7 thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2603661157","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603661157?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:56","pubTimestamp":1768398969,"startTime":"0","endTime":"0","summary":"CNBX Pharmaceuticals Inc. reported its earnings for the three months ended November 30, 2025. The company recorded a net loss of USD 113,719 for the quarter. Cash used in operations totaled USD 47,408 during the same period. CNBX Pharmaceuticals Inc. continues to focus on the development of its lead drug candidate, RCC-33, for colorectal cancer, with plans to initiate first-in-human Phase I/II clinical trials in 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNBX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 14, 2026, and is solely responsible for the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL44qyfL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}]}}